Figures as of 30 September 2026. General information, not tax, legal, or regulatory advice. bioaccess® is not affiliated with any Lithuanian authority or institution. Tax and regulatory rules change; confirm current terms with qualified advisers.
Lithuania offers EU-harmonized first-in-human regulation (MDR for devices, CTIS for drugs), a triple deduction of qualifying R&D costs, and CRO labor costs reported 62% below the EU average of €1M per year. But the tax benefit is a deduction, not a cash rebate — it reduces Lithuanian taxable income and does little for a U.S. startup with no Lithuanian profits — and device investigations run the EU national process through the competent authority plus ethics review, with the sponsor established in the EU or represented by an EU legal representative. bioaccess® compares on gross, cash cost in Latin America with U.S. FDA anchoring and no EU entity. Figures as of September 2026; general information, not tax, legal, or regulatory advice.
| Metric | bioaccess® | Lithuania |
|---|---|---|
| Headline draw | Lowest gross (cash) cost, U.S. FDA anchoring, no EU entity to establish, and same- or near-U.S. time-zone proximity | EU-harmonized FIH inside the EU system: MDR for devices, CTIS for drugs, a triple deduction of qualifying R&D costs, and CRO labor reported 62% cheaper than the EU average |
| Start-up pathway | First patient typically 4–8 months after protocol (illustrative). Ethics in a median of 4–8 weeks | Device investigations: EU MDR clinical-investigation application to the national competent authority (the State Health Care Accreditation Agency, VASPVT) plus ethics committee review. Drug trials: ethics opinion within 30 days; competent-authority and ethics permissions average ~60 days total, under the EU Clinical Trials Regulation (CTIS) |
| Gross (cash) cost | Lowest cost base — per-patient $15K–$35K versus $40K–$75K typical US/EU (our published benchmarks) | Lower than Western Europe: CRO labor reported 62% below the EU average of €1M per year — but still a euro-denominated EU cost base with EU site overhead |
| Effect of the tax benefit | No incentive needed — you pay only for work delivered, with no financing lag | A triple deduction cuts Lithuanian taxable income (with 2-year depreciation for R&D assets and a reduced CIT rate on commercializing R&D-created IP) — but a deduction is not a cash rebate: it helps only against Lithuanian profits |
| Entity requirement | None — contract and start | Under the MDR, a non-EU sponsor must designate a legal representative established in the EU |
| Notified-body access | Full-service CRO runs the file end to end | No notified bodies are based in Lithuania; CE conformity assessment routes through notified bodies in other member states |
| Site pool | 19 Latin American & Caribbean countries | Small, concentrated pool: 40–60 trials per year nationally (GlobalData), centered on Vilnius and Kaunas |
| Distance & time zone from the U.S. | Same or adjacent U.S. time zones; ~3–8 hour flights | Vilnius is ~7 hours ahead of U.S. Eastern — week-to-week oversight runs on European hours |
| FDA acceptance & data applicability | Data conducted under GCP (ISO 14155 for devices; ICH E6 for drugs) is eligible for FDA consideration under 21 CFR 812.28 or 312.120, case-by-case | Also FDA-eligible; FDA and PMDA assess data applicability case-by-case regardless of which region hosts the trial |
| Where it is genuinely stronger | Lowest cash-basis cost, no EU entity, same region carries later patient-phase work | The FIH dataset is generated inside the EU system — attractive when the pivotal plan is EU-bound — with EU-harmonized ethics review |
The Lithuania column quotes the public sources listed below. The bioaccess® column comes from bioaccessla.com and reflects our FIH-12™ operating model.
Lithuania's pitch is real, and for the right sponsor it's the most cost-efficient EU entry point for first-in-human. EU-harmonized regulation, a concentrated investigator pool, and a tax code that visibly rewards R&D. But the tax benefit needs honest translation: a triple deduction means each euro of qualifying R&D spend reduces Lithuanian taxable income by three euros — it is a deduction, not a cash rebate. It is worth real money against Lithuanian profits, and worth nothing in near-term cash to a pre-revenue U.S. startup with no Lithuanian tax base. The standard corporate rate rises to 17% for financial years starting 2026, which changes the arithmetic slightly in the deduction's favor — for companies that actually pay Lithuanian tax.
The regulatory reality is equally honest. Device first-in-human runs the EU MDR clinical-investigation process at national level: application to the competent authority — the State Health Care Accreditation Agency (VASPVT) — plus ethics committee review, with no notified bodies based in Lithuania, so CE conformity work routes through other member states. For drug trials, the published Lithuanian experience is an ethics opinion within 30 days and combined permissions averaging ~60 days, now under the EU Clinical Trials Regulation via CTIS. We will not invent a Lithuania-specific device FIH start-up median — ask for a study-specific calendar. And under the MDR, a non-EU sponsor must designate a legal representative established in the EU: there is no FIH in Lithuania without EU presence of some form.
Where Lithuania is genuinely stronger, we say so: if your pivotal strategy is EU-bound and you want the FIH dataset generated inside the EU system, if you have Lithuanian profits for the triple deduction to work against, or if you already operate in the EU and the MDR/CTIS machinery is familiar — Lithuania is a legitimate, lower-cost EU choice. bioaccess® is the better fit when the goal is the fastest, lowest-gross-cost route to FDA-bridgeable human data without standing up EU presence: U.S. regulatory anchoring from Miami, execution across Latin America in your own time zones, and the same regional infrastructure that carries later patient-phase work. Data is generated under GCP (ISO 14155 for devices; ICH E6 for drugs) and is eligible for FDA consideration under 21 CFR 812.28 or 312.120 — a case-by-case determination, not a guarantee of acceptance.
Figures on this page are as of September 2026 and are general information, not tax, legal, or regulatory advice; sponsors should confirm current rules with qualified advisers.
Lithuania allows qualifying R&D costs to be deducted at three times their amount, offers 2-year depreciation for fixed assets used in R&D, and applies a reduced corporate-income-tax rate to profits from commercializing R&D-created IP. The key mechanics: a deduction reduces taxable income — it is not a refundable credit. It delivers cash value only against Lithuanian taxable profits, so a U.S. startup with no Lithuanian profits gets no near-term benefit. The standard CIT rate rises from 16% to 17% for financial years starting 2026. This is general information, not tax advice.
For drug trials, published Lithuanian experience is an ethics opinion within 30 days with combined competent-authority and ethics permissions averaging ~60 days total — now running under the EU Clinical Trials Regulation via CTIS, where sponsors can also begin site contracting and logistics before approval. For device first-in-human, the EU MDR clinical-investigation process applies at national level (competent authority plus ethics committee); there is no published Lithuania-specific device FIH median, and we will not invent one. Ask for a study-specific calendar.
Under the EU MDR, where the sponsor is not established in the EU it must designate a legal representative established in the EU — so some form of EU presence is required; there is no FIH in Lithuania without it. bioaccess®'s Latin American programs require no foreign entity at all: contract and start. This is general information, not legal advice.
Yes — foreign clinical data from either region can support a U.S. submission when it meets the applicable requirements (21 CFR 812.28 for devices, 21 CFR 312.120 for drugs, conducted under GCP). Acceptance is determined by the FDA case-by-case, subject to its data-validation and supporting-information requirements, not by the country of origin.
…your pivotal strategy is EU-bound and you want the FIH dataset generated inside the EU regulatory system, you have (or will have) Lithuanian taxable profits for the triple R&D deduction to work against, or you already operate in the EU and the MDR/CTIS process is familiar rather than a new burden. If instead you want the fastest, lowest-gross-cost route to FDA-bridgeable human data without EU presence — close to your time zone, in the same region that carries your later patient phases — bioaccess® in Latin America is built for that.
Related: Paraguay · New Zealand · Israel
All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call